


AMENDMENT TO THE CLAIMS

Please cancel claims 3 and 4.

Please enter rewritten claims 1, 2, 5 and 6 as provided below.

1. (Currently Amended) A method for the treatment of migraine disorders ~~responsive to opening of the KCNQ potassium channels in a mammal in need thereof,~~ which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I



wherein

R¹ is selected from hydrogen, halogen, C₁₋₈alkyl, phenyl, phenylalkyl, C₃₋₆heterocyclic, C₃₋₆heterocyclicmethyl, -CN, -OR, -NRR, -NRNCOR or -CF₃;

R² is selected from halogen, C₁₋₈alkyl, C₃₋₇cycloalkyl, phenyl, phenylalkyl, C₃₋₆heterocyclic, C₃₋₆heterocyclicmethyl, -CN, -OR, -NRR, -NRNCOR or -S-R;


R³ is selected from hydrogen, halogen or C₁₋₈alkyl;

R⁴ is selected from hydrogen, -CH₃ or -CH₂C₆H₅;

R⁵ is selected from hydrogen, C₁₋₈alkyl, C₃₋₇cycloalkyl, phenyl, phenylalkyl, C₃₋₆heterocyclic or C₃₋₆heterocyclicmethyl;

wherein each occurrence of R is independently selected from the group consisting of C₁₋₈alkyl, C₃₋₇alkynyl, phenyl, phenylalkyl, C₃₋₆heterocyclic and C₃₋₆heterocyclicmethyl.

2. (Currently Amended) ~~The of claim 1 wherein the compound of Formula I is selected from a compound having the structure~~ A method for the treatment of migraine in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I



wherein

R¹ is hydrogen;

R² is selected from the group consisting of NR⁶R⁷, SR⁸, OR⁹, phenyl, and thienyl; in which said phenyl is optionally substituted with one or two C₁₋₃alkoxy groups;

R³ is selected from the group consisting of C₁₋₆alkyl, trifluoromethyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylmethyl, phenyl, amino, di(C₁₋₃alkyl)amino and pyrrolidinyl; in which said phenyl is optionally substituted with a halogen;

R⁴ is selected from the group consisting of phenylmethyl, furanylmethyl, and C₃₋₇cycloalkylmethyl; in which the phenyl of said phenylmethyl is optionally substituted with one substituent selected from the group consisting of halogen, C₁₋₃alkyl, di(C₁₋₃alkyl)amino, trifluoromethyl, trifluoromethoxy, and trifluoromethylthio; and in which the furanyl of said furanylmethyl is optionally substituted with a C₁₋₃alkyl group;

R⁵ is hydrogen;

R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇alkynyl, phenyl, and phenylmethyl; in which said C₁₋₆alkyl is optionally substituted with a hydroxy group and in which said phenyl is optionally substituted with one or two substituents selected from the group consisting of halogen, trifluoromethoxy, and nitro; or R⁶ and R⁷ taken together with the nitrogen to which they are attached form a heterocyclic ring selected from the group consisting of pyrrolidinyl, morpholinyl, piperidinyl, homopiperidinyl, methylpiperidinyl, and 1,2,3,4-tetrahydroisoquinolinyl;

R⁸ is selected from the group consisting of C₁₋₆alkyl, C₃₋₇cycloalkyl, phenyl, phenylmethyl, furanylmethyl, and thienyl; in which said phenyl is optionally

substituted with one halogen or nitro group; and wherein the phenyl of said phenylmethyl is optionally substituted with one halogen or C₁₋₃alkyl group; and R⁹ is selected from the group consisting of C₃₋₇alkynyl, phenyl, 1-(4-fluorophenyl)ethyl, and thienylmethyl; in which said phenyl is optionally substituted with a halogen or C₁₋₃alkoxy group.

3. (Cancelled)

4. (Cancelled)

5. (Currently Amended) A pharmaceutical composition for the treatment of migraine ~~disorders responsive to opening of KCNQ potassium channels~~ comprising a therapeutically effective amount of the compound of claim 1 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.

6. (Currently Amended) A pharmaceutical composition for the treatment of migraine ~~disorders responsive to opening of KCNQ potassium channels~~ comprising a therapeutically effective amount of the compound of claim 2 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.